Bio-Path (NASDAQ:BPTH) Now Covered by Analysts at StockNews.com

StockNews.com initiated coverage on shares of Bio-Path (NASDAQ:BPTH) in a research report released on Wednesday morning. The brokerage issued a sell rating on the stock.

Separately, Roth Mkm reissued a buy rating and set a $40.00 target price on shares of Bio-Path in a research note on Thursday, April 18th.

Bio-Path Stock Down 7.3 %

Shares of NASDAQ:BPTH opened at $2.49 on Wednesday. Bio-Path has a fifty-two week low of $2.46 and a fifty-two week high of $44.80. The firm has a 50-day simple moving average of $5.01 and a 200 day simple moving average of $8.42. The company has a market cap of $1.69 million, a PE ratio of -0.06 and a beta of 0.35.

Bio-Path (NASDAQ:BPTH) last announced its quarterly earnings data on Friday, March 8th. The company reported ($5.40) earnings per share for the quarter, meeting analysts’ consensus estimates of ($5.40). During the same quarter in the prior year, the company posted ($10.60) EPS. As a group, research analysts forecast that Bio-Path will post -18.71 EPS for the current fiscal year.

Bio-Path Company Profile

Bio-Path Holdings, Inc operates as a clinical and preclinical stage oncology focused RNAi nanoparticle drug development company in the United States. The company develops products based on DNAbilize, a drug delivery and antisense technology platform that uses P-ethoxy, which is a deoxyribonucleic acid (DNA) backbone modification intended to protect the DNA from destruction.